Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination by 議곗긽�옒
  
2006, 74(8):4954. DOI: 10.1128/IAI.01781-05. Infect. Immun. 
Young-Chul Sung and Sang-Nae Cho
Byong-Moon Kim, Sung-Hee Lee, Won-Bae Kim,
Hyang-Ju Kang, Eun-Gae Lee, Soon-Geon Kwon, 
Sang-Jun Ha, Su-Hyung Park, Hye-Ju Kim, Seung-Chul Kim,
 
Vaccination
plus AS01B in Tuberculosis Subunit 
Interleukin-12-Encapsulated Microspheres
Efficacy with the Use of 
Enhanced Immunogenicity and Protective
http://iai.asm.org/content/74/8/4954
Updated information and services can be found at: 
These include:
SUPPLEMENTAL MATERIAL
 Supplemental material
REFERENCES
http://iai.asm.org/content/74/8/4954#ref-list-1at: 
This article cites 30 articles, 16 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 June 18, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://iai.asm
.org/
D
ow
nloaded from
 
 o
n
 June 18, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://iai.asm
.org/
D
ow
nloaded from
 
INFECTION AND IMMUNITY, Aug. 2006, p. 4954–4959 Vol. 74, No. 8
0019-9567/06/$08.000 doi:10.1128/IAI.01781-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Enhanced Immunogenicity and Protective Efficacy with the Use
of Interleukin-12-Encapsulated Microspheres plus AS01B
in Tuberculosis Subunit Vaccination§
Sang-Jun Ha,1† Su-Hyung Park,1 Hye-Ju Kim,1 Seung-Chul Kim,2 Hyang-Ju Kang,1 Eun-Gae Lee,2
Soon-Geon Kwon,2 Byong-Moon Kim,3 Sung-Hee Lee,3 Won-Bae Kim,3
Young-Chul Sung,1*‡ and Sang-Nae Cho2,4*‡
Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology, San 31 Hyoja-dong,
Pohang 790-784, Korea1; Department of Microbiology and Brain Korea 21 Project for Medical Sciences,
Yonsei University College of Medicine, 134 Shinchon-dong, Seoul 120-752, Korea2; Research Laboratories,
Dong-A Pham. Co., Ltd., Yongin-si, Kyunggi-do 449-900, Korea3; and
The International Vaccine Institute, Seoul 151-600, Korea4
Received 3 November 2005/Returned for modification 20 December 2005/Accepted 19 May 2006
Tuberculosis subunit vaccines codelivered with interleukin-12 (IL-12)-encapsulated microspheres (IL-
12EM) are designed for a sustained release of IL-12 and could induce strong Th1 immune responses specific
to Ag85A and ESAT-6. The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce
a sustained Th1 immunity and protection against Mycobacterium tuberculosis.
Since the Mycobacterium bovis bacillus Calmette-Gue´rin
(BCG) vaccine has shown little effectiveness against tubercu-
losis (TB) in adults (4), the development of an effective TB
vaccine to prevent M. tuberculosis infection is urgently needed.
Subunit vaccines against tuberculosis show some promise but
require coadministration of adjuvants to stimulate a Th1 im-
mune response, which plays a key role in protection against M.
tuberculosis infection. Although interleukin-12 (IL-12) has
been reported to induce a strong Th1 immune response, the in
vivo use of recombinant IL-12 (rIL-12) protein as an adjuvant
of subunit vaccines was not sufficient to improve both Th1
immune response and protection, due to its rapid in vivo clear-
ance and inactivation. The use of IL-12-encapsulated micro-
spheres (IL-12EM) could be a solution that overcomes the
rapid in vivo clearance of IL-12 protein, because cytokine-
encapsulated biodegradable polymer microspheres have been
known to achieve local and sustained expression of therapeutic
agents, including cytokines (6, 8, 11, 12, 18, 20, 30). We eval-
uated IL-12EM as an adjuvant in a TB subunit vaccine model.
In addition, we examined the combined adjuvant effect of
IL-12EM plus AS01B, another Th1-inducing adjuvant, which is
composed of monophosphoryl lipid A (MPL) and saponin
molecule (QS21) (2, 21).
rIL-12 was encapsulated into poly(DL-lactic-co-glycolic acid)
(PLGA) microspheres by use of a water-in-oil-in-water double-
emulsion solvent evaporation technique (5, 13, 14). An aque-
ous solution of rIL-12 (50 g) and bovine serum albumin (12.5
mg) was emulsified in dichloromethane containing 500 mg of
PLGA. The amount of IL-12 incorporated into microspheres
was determined using an enzyme-linked immunosorbent assay
(ELISA) after dissolving IL-12EM in dimethyl sulfoxide. Fig-
ure 1 shows in vivo release of IL-12 from IL-12EM at different
time points. The burst release of IL-12 in mice injected with
rIL-12 was observed within 30 min, but the levels declined
rapidly. In contrast, the release of IL-12 from IL-12EM was
persistent after 9 days, indicating that encapsulation of rIL-12
using PLGA was effective, and a slow release of IL-12 could be
achieved in vivo using IL-12EM.
To test the adjuvant effect of IL-12EM in the TB subunit
vaccine, we used Ag85A and ESAT-6 (AE) as subunit vac-
cine components because they are known to be protective
antigens that induce a strong Th1 immune response (17, 28).
Each subunit of vaccine contained 20 g of Ag85A protein and
15 g of ESAT-6 protein (Standardia Diagnostics, Inc., Suwon,
Korea) and was emulsified in either alum (Pierce, Rockford,
IL) or AS01B (SmithKline Beecham Biologicals S.A., Bel-
gium) with or without IL-12EM containing 0.1 g of IL-12.
Mice were immunized with the experimental vaccines by a
dorsal, subcutaneous route at 0 and 8 weeks. End-point titers
of antibodies specific to Ag85A and ESAT-6 were determined
using serum ELISA at 4 weeks after the primary immunization
(Table 1). The alum-immunized (AE/alum) group showed
higher levels of total immunoglobulin G (IgG) (fourfold) and
IgG1 (eightfold) specific to Ag85A than the AS01B-immu-
nized (AE/AS01B) group. However, the IgG2a level was
fourfold lower in the alum-immunized group than in the
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AS01B-immunized group, indicating that alum induces a Th2-
type antibody response rather than a Th1-type response. Coin-
jection of IL-12EM with alum (alumIL-12EM) or AS01B
(AS01BIL-12EM) increased IgG2a preferentially over IgG1.
While the levels of Ag85A-specific IgG2a in groups with IL-
12EM were 128- to 256-fold higher than the levels in groups
without IL-12EM, the IgG1 levels were increased two- to
eightfold. The AS01BIL-12EM-immunized group showed a
1,024-fold-higher level of IgG2a than but the same level of
IgG1 as the alum-immunized group. After secondary immuni-
zation, alum-injected mice still showed a lower IgG2a response
than AS01B-injected mice. The AS01BIL-12EM-immunized
group showed the highest ratio of IgG2a to IgG1 specific to
Ag85A (125 and 1,000 for primary and secondary responses,
respectively), suggesting that a strong Th1 immunity would be
established in this group (Table 1). A similar pattern of IgG
subtype distribution was observed with the ESAT-6-specific
antibody responses. Although little is known about the role of
antibody subtypes in the control of tuberculosis, there are
some reports showing that the IgG2a isotype is associated with
a Th1 cytokine response (22, 23). Furthermore, the induction
of Th1 cellular immunity strongly correlates with protective
immunity against M. tuberculosis (25). Interestingly, the BCG-
immunized group showed low levels of Ag85A-specific total
IgG and IgG1 responses and no IgG2a production, indicating
that BCG immunization itself could not effectively induce the
antibody responses specific to Ag85A, a major protein of cul-
ture filtrate protein (CFP). Also, the ESAT-6-specific response
could not be induced after BCG immunization because BCG
lacks the ESAT-6-encoding gene.
To investigate the adjuvant effect of IL-12EM on the induc-
tion of the Th1 immune response, a gamma interferon (IFN-)
enzyme-linked immunospot (ELISPOT) assay was performed
using lymphocytes from spleens (Fig. 2A) and draining lymph
nodes (Fig. 2B). BCG-immunized mice had a threefold-higher
level of IFN- specific to CFP than to Ag85A. This is unlike
other subunit vaccine-immunized mice, which indicates that
CFP-specific T-cell responses induced by BCG vaccination
may be comprised of responses specific to TB antigens other
than Ag85A. The pattern observed in the IgG2a responses of
alum- and AS01B-injected groups was also found in the IFN-
response. AS01B, but not alum, induced Ag85A-, ESAT-6-,
and CFP-specific Th1 immune responses. The IL-12EM com-
bination with alum or AS01B also led to the enhancement of
IFN- production. It is worthwhile to note that overall IFN-
responses are observed to be higher in spleens than in draining
lymph nodes. This suggests that, as shown in the previous
reports, effector memory cells during a secondary response are
preferentially enriched in nonlymphoid tissues and spleens
FIG. 1. In vivo release of IL-12 from IL-12EM. Mice were injected
subcutaneously (s.c.) with 0.5 g of rIL-12 or IL-12EM containing the
same amount of IL-12. At the indicated time points after injection (d,
days), IL-12 concentration in serum was measured by ELISA.
TABLE 1. Antibody end-point titers and IgG2a/IgG1 ratios for the immunized micea
Antibody Vaccine groupb
Primary antibody response
(end-point titer)c Ratio of IgG2a
to IgG1d
Secondary antibody response
(end-point titer)c Ratio of IgG2a
to IgG1d
Total IgG IgG1 IgG2a Total IgG IgG1 IgG2a
Anti-Ag85A PBS 8e 8 8 8 8 8
BCG 128 128 8 128 128 8
AE/alum 32,768 1,048,576 128 0.1 524,288 8,388,608 4,096 0.5
AE/AS01B 8,192 131,072 512 3.9 1,048,576 8,388,608 131,072 15.6
AE/alumIL-12EM 262,144 2,097,152 16,384 7.8 2,097,152 16,777,216 262,144 15.6
AE/AS01BIL-12EM 1,048,576 1,048,576 131,072 125.0 4,194,304 2,097,152 2,097,152 1,000.0
Anti-ESAT-6 PBS 8 8 8 8 8 8
BCG 8 8 8 8 8 8
AE/alum 131,072 1,048,576 4,096 3.9 1,048,576 16,777,216 32,768 2.0
AE/AS01B 16,384 16,384 4,096 249.9 524,288 1,048,576 131,072 125.0
AE/alumIL-12EM 1,048,576 2,097,152 32,768 15.6 4,194,304 16,777,216 262,144 15.6
AE/AS01BIL-12EM 2,097,152 524,288 524,288 1,000.0 4,194,304 4,194,304 1,048,576 250.0
a Serum samples were obtained from peripheral blood of the mice in each group (20 to 28 mice per group). Sera from mice in the same group were pooled with the
same volume of individual sera.
b C57BL/6 mice were subcutaneously immunized once with BCG (107 CFU) at 0 weeks or injected twice at 8-week intervals with the experimental subunit vaccines
in different adjuvant combinations. PBS, phosphate-buffered saline.
c Total IgG, IgG1, and IgG2a end-point titers obtained using the serum pool from each group were determined by ELISA and are represented as serum dilutions
(n-fold). Primary antibody responses were measured at 4 weeks after priming with the indicated vaccines. Secondary antibody responses were measured at 4 weeks after
boosting with the indicated vaccines.
d For the calculation of the ratio of IgG2a to IgG1, the end-point titer of IgG2a was divided by that of IgG1 and then multiplied by 1,000.
e Undetectable antibody level in serum diluted eightfold.
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rather than in lymph nodes (16, 19, 26, 27). To evaluate the
peripheral immune response of the lungs as a primary infection
site of M. tuberculosis, we performed intracellular IFN- stain-
ing for CD4 T cells isolated from lungs (Fig. 2C). Similarly to
the results observed with the ELISPOT assay, the highest num-
bers of IFN--secreting CD4 T cells (2.90% and 5.26% of
CD4 T cells after stimulation with Ag85App and ESAT-6p,
respectively) were detected in the AS01BIL-12EM group.
This indicates that this combination is effective in generating
peripheral Th1 immune responses as well as systemic Th1
immune responses.
To investigate whether the immune response enhanced by
IL-12EM can lead to increased protection against tubercu-
losis, the mice were challenged aerogenically with two dif-
ferent doses of M. tuberculosis at 16 weeks after the first
immunization. The subsequent course of infection was mon-
itored in the lung, the primary site of infection (Fig. 3).
BCG-immunized mice had threefold fewer bacteria than
saline-immunized mice after a high-dose challenge (Fig. 3A)
(P of 0.001 and P of 0.01 at 4 and 9 weeks postchallenge,
respectively). While alum did not reduce the bacterial load,
AS01B slightly reduced the bacterial number by 1.5-fold on
average at 4 weeks compared with saline, although the dif-
ference was not statistically significant. In contrast, the two
groups containing IL-12EM exhibited significantly reduced
bacterial numbers compared to the saline group at 4 weeks
(1.7-fold [P  0.05] and 5.4-fold [P  0.001] for alumIL-
12EM- and AS01BIL-12EM-immunized groups, respec-
tively). The growth control in the AS01BIL-12EM-immu-
nized group was better than that in the BCG-immunized
group (1.7-fold, P  0.05). The reduction of bacterial loads
in saline control mice at 9 weeks compared to that at 4
weeks might be due to acquired immunity induced by M.
tuberculosis infection. At 9 weeks postchallenge, the mice
immunized with BCG or subunit vaccines showed a statisti-
cally significant decrease in bacterial numbers compared
with saline-immunized mice (P  0.05 for all groups). This
suggests that the vaccine-induced memory immune response
FIG. 2. Effect of experimental TB subunit vaccines on IFN- immune responses. Mice were subcutaneously immunized at 0 and 8 weeks with
recombinant Ag85A and ESAT-6 proteins in different adjuvant combinations, or they received a BCG vaccination. Eight weeks after the last
immunization, spleens (A) and draining lymph nodes (DLN) from abdominal and mediastinal sites (B) from three mice were pooled and used in
an ELISPOT assay to determine the numbers of cells secreting IFN- in response to media, Ag85A peptide pool (Ag85App, 20-mer peptides
overlapping by 10 amino acids; 1 g/ml for each peptide), ESAT-6 peptide (3, 29) (ESAT-6p, CD4 epitope; 10 g/ml), or CFP (10 g/ml). The
numbers of IFN--producing cells per 106 splenocytes are represented as the average spot-forming cells (SFC) (standard deviations) in triplicate
wells. These results were reproduced in two independent experiments. (C) Lung lymphocytes from the same mice were pooled and stimulated in
vitro for 5 h with media, Ag85App, or ESAT-6p in the presence of syngeneic spleen antigen-presenting cells. After being stained with anti-CD4,
anti-CD44, and anti-IFN-, live CD4 T cells were gated and analyzed for intracellular IFN- expression (y axis) and CD44 activation marker (x
axis) by flow cytometry. The percentages of both IFN-- and CD44-positive CD4 T cells were calculated and are shown within each plot. The
data represent two independent experiments with similar results.
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was boosted by the M. tuberculosis challenge and that the
immune response could control bacterial growth. Also,
within this time period, BCG- and AS01BIL-12EM-immu-
nized groups showed 3.4-fold- and 4.9-fold-lower numbers
of bacteria, respectively, than the saline-treated group (P 
0.01 for both). In cases of low-dose infection (Fig. 3B), the
numbers of bacteria were reduced in the AS01B-, alumIL-
12EM-, and AS01BIL-12EM-immunized groups com-
pared to numbers in the control group. Alum-immunized
mice did not show a meaningful protective efficacy at either
4 or 9 weeks. The difference in adjuvant protection effects
between alum versus AS01B was definitive in the low-dose-
challenge experiment. AS01BIL-12EM was superior to
BCG at 4 and 9 weeks (4.4-fold, P  0.05, and 9.5-fold, P 
0.01, respectively). Reviewing the histopathology, a substan-
tial portion of the air spaces in the lungs was filled with
monocytes at 4 weeks of infection in control mice, but no
significant difference was found between experimental groups de-
spite a significant difference in bacterial loads (data not shown).
This might be due to the infiltration of monocytes into the area of
M. tuberculosis infection regardless of the bacterial number in the
lesions. Bacterial loads in the spleen were lower than those in
the lung. The differences between groups were less significant in
the lung data, because bacteria were administered via an aerosol
FIG. 3. Protection against M. tuberculosis by immunization with experimental TB vaccines. Mice were subcutaneously immunized at 0 and
8 weeks with recombinant Ag85A and ESAT-6 proteins in different adjuvant combinations. Positive-control mice received a single
subcutaneous injection of M. bovis BCG at the first immunization. Eight weeks after the last immunization, mice were aerogenically
challenged with high-dose (240 CFU per lung) (A) or low-dose (20 CFU per lung) (B) M. tuberculosis H37Rv using a previously described
method (10). The numbers of live bacilli in the lungs of four to seven mice per group were assessed at 4 and 9 weeks (wks) after the challenge.
The data are presented as mean CFU (standard errors of the means). The lower limit of detection was 102 per organ. Thus, some organs
which had 0 CFU on plates seeded with undiluted samples in the low-dose-infection experiment were scored with a CFU of 102 for statistical
purposes. The levels of statistical significance for differences between test groups and the saline control group were determined by Student’s
t test (*, P  0.05; **, P  0.01; ***, P  0.001). The levels of significance of the differences between the AE/AS01BIL-12EM group
and BCG group are shown above the bars.
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route (supplemental Fig. 1). After aerosol administration of M.
tuberculosis, the mice given subunit vaccines together with differ-
ent adjuvants displayed a pattern of IFN- response similar to
that observed before the challenge. However, saline-treated mice
also showed a substantial IFN- response. This suggests that the
antigen-specific IFN- response observed postchallenge might re-
flect not only the recall response but also the response elicited by
the remaining bacteria (supplemental Fig. 2).
Our study is the first report demonstrating that the use of
IL-12EM as an adjuvant in a TB subunit vaccine model is
effective in the establishment of an antigen-specific Th1
immune response and protection against M. tuberculosis.
Protection induced by the subunit vaccine combined with
AS01BIL-12EM appeared to be superior to that achieved
by conventional BCG, suggesting that this adjuvant combi-
nation has clinical potential. Although the importance of
IL-12 in the induction of Th1 immune response and the
control of M. tuberculosis has been widely accepted, the
adjuvant effect of rIL-12 in subunit vaccines appears to be
transient (9, 15, 24). Recent reports clearly demonstrate
that continuous IL-12 production is necessary for main-
tenance of the pulmonary Th1 cells required for the control
of persistent M. tuberculosis infection (7). We also found
that codelivery of IL-12EM could induce higher Th1 and
CD8 T-cell responses than that of rIL-12 in hepatitis B
virus and influenza subunit vaccine models (unpublished
data). A precondition for the successful implementation of
TB subunit vaccines is the generation of long-term T-cell
memory response. In contrast to previous TB subunit vac-
cines (1), our subunit vaccine combined with AS01BIL-
12EM could sustain antigen-specific Th1 responses 8 weeks
after the last immunization. This may be caused by IL-12EM
since it is known that long-term expression of IL-12 can
maintain the memory T-cell response (9, 24). Our promising
results may lay the groundwork for introducing such vac-
cines as a practical alternative to BCG in the near future.
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